3D Spheroid Assays for Cancer Drug Screening
AMSBIO has introduced a new range of 96-well format 3D Spheroid Cell Proliferation/Viability Assays, providing a new tool to allow cell-based assays to be done in 3D.
The new AMSBIO 3D Spheroid Proliferation/Viability Assay provides a useful tool for modeling tumor response in vitro. The kit uses a 3D Culture Qualified 96-Well Spheroid Formation Plate alongside a specialized Spheroid Formation Extracellular Matrix to drive aggregation and/or spheroid formation of cells.
Upon completion of spheroid formation, the spheroid may be treated with pharmacological agents to evaluate tumor viability after drug treatment. Tumor spheroid expansion is visualized microscopically and can be quantitated through image analysis software for real-time and label free evaluation.
At the conclusion of the assay, cell viability may be assessed by fluorescence using Resazurin. The 3D Spheroid Fluorometric Proliferation/Viability Assay offers an in vitro, standardized, three-dimensional, high content format for inducing multicellular tumor spheroid (MCTS) formation and quantitating cell viability within the spheroids in response to pharmacological treatment.
The AMSBIO 3D Spheroid Proliferation/Viability Assay establishes physiological gradients for nutrients, oxygen, catabolites, and pH due to limitations in diffusion through multicellular layers. These gradients also promote the creation of heterogeneous cell populations with proliferating cells on the spheroid surface, quiescent cells in the intermediate layers, and necrotic cells in the core, similar to an avascular tumor. Uniform spheroid size and physiology is determined through cell seeding, providing a robust and reproducible assay format for drug screening or pathway analysis.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...